{"organizations": [], "uuid": "4d45458d88b22f107a19f190765aad4016afe1fc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-otonomy-sees-2017-non-gaap-expense/brief-otonomy-sees-2017-non-gaap-expenses-totaling-73-78-million-idUSASB0C0BV", "country": "US", "domain_rank": 408, "title": "BRIEF-Otonomy Sees 2017 Non-Gaap Expenses Totaling $73-$78 Million", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-09T14:44:00.000+02:00", "replies_count": 0, "uuid": "4d45458d88b22f107a19f190765aad4016afe1fc"}, "author": "", "url": "https://www.reuters.com/article/brief-otonomy-sees-2017-non-gaap-expense/brief-otonomy-sees-2017-non-gaap-expenses-totaling-73-78-million-idUSASB0C0BV", "ord_in_thread": 0, "title": "BRIEF-Otonomy Sees 2017 Non-Gaap Expenses Totaling $73-$78 Million", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "otonomy inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 9 (Reuters) - Otonomy Inc:\n* OTONOMY INC - EXPECTS GAAP OPERATING EXPENSES FOR 2017 TO TOTAL IN RANGE OF $95-$100 MILLION\n* OTONOMY PROVIDES CORPORATE AND PRODUCT PIPELINE UPDATE * OTONOMY INC - SEES 2017 NON-GAAP EXPENSES TOTALING $73-$78 MILLION\n* OTONOMY - CASH BALANCE INCLUDING CASH, CASH EQUIVALENTS, & SHORT-TERM INVESTMENTS TOTALED $120 MILLION AT END OF 2017\n* OTONOMY SAYS CASH BALANCE EXPECTED TO FUND COMPLETION OF CLINICAL DEVELOPMENT REQUIRED FOR U.S. REGISTRATION OF OTIVIDEX IN MÉNIÈRE‘S DISEASE Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": [], "published": "2018-01-09T14:44:00.000+02:00", "crawled": "2018-01-09T15:03:12.005+02:00", "highlightTitle": ""}